-

10:49:27 AM

PBYI Stock News

PBYI - Puma Biotechnology Inc

08/05/22 5:15 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma’ s Board of Directors approved the grant of inducement restricted stock unit awards covering 37,250 shares of Puma common stock to six new non-executive employees. Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on...

RHEA-AI

very positive

08/04/22 4:05 PM

Nasdaq : PBYI

earnings

Puma Biotechnology Reports Second Quarter 2022 Financial Results

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2022. Based on accounting principles generally accepted in the United States, Puma reported net income of $9.4 million, or $0.21 per basic and diluted share, for the second quarter of 2022, compared to a net loss of $5.1 million, or $0.13 per...

RHEA-AI

neutral

07/21/22 4:11 PM

Nasdaq : PBYI

conferencesearnings

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/ 4:30 p.m. EDT on Thursday, August 4, 2022, following the release of its second quarter 2022 financial results. Please dial in at least 10 minutes in advance and inform the operator that you would like to join the“ Puma Biotechnology Conference Call.” A live webcast...

RHEA-AI

neutral

07/06/22 5:15 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 1, 2022, the Compensation Committee of Puma’ s Board of Directors approved the grant of inducement restricted stock unit awards covering 30,875 shares of Puma common stock to six new non-executive employees. Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on...

RHEA-AI

very positive

06/07/22 5:31 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 3, 2022, the Compensation Committee of Puma’ s Board of Directors approved the grant of inducement restricted stock unit awards covering 38,125 shares of Puma common stock to six new non-executive employees. Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on...

RHEA-AI

very positive

06/06/22 9:05 AM

Nasdaq : PBYI

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Puma Biotechnology, Inc., a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in patients with hormone receptor positive, HER2-negative, HER2- mutant metastatic breast cancer, at the 2022 American Society of Clinical Oncology Annual Meeting held in person...

RHEA-AI

positive

06/04/22 9:05 AM

Nasdaq : PBYI

clinical trial

Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting

Puma Biotechnology, Inc., a biopharmaceutical company, presented final results from the Phase II SUMMIT‘ basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations at the 2022 American Society of Clinical Oncology Annual Meeting. The presentation entitled“...

RHEA-AI

neutral

05/26/22 5:05 PM

Nasdaq : PBYI

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting

Puma Biotechnology, Inc., a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology Annual Meeting. Abstract 4079: Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: final results from the phase 2 SUMMIT‘ basket’ trial JJ Harding, S...

RHEA-AI

neutral

05/11/22 5:31 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 9, 2022, the Compensation Committee of Puma’ s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,500 shares of Puma common stock to three new non-executive employees. Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on...

RHEA-AI

very positive

05/05/22 4:05 PM

Nasdaq : PBYI

earnings

Puma Biotechnology Reports First Quarter 2022 Financial Results

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022. Based on accounting principles generally accepted in the United States, Puma reported net loss of $3.4 million, or $0.08 per basic and diluted share, for the first quarter of 2022, compared to net income of $16.5 million, or $0.41 per...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

PBYI Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.pumabiotechnology.com
Security namePuma Biotechnology Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees267
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Puma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.